Kevin McDermott
Chief Commercial Officer
Expertise:
Kevin started his career in sales and marketing and for the past two decades, led market access functions across multiple biopharma organizations. He has a track record of building and leading customer-centric, highly collaborative and focused teams.
Kevin has deep broad commercialization experience and has led teams on the Lipitor®, Welchol®, Fluzone®, Benicar®, Effient®, Zenpep® and Arikayce® brands.
Kevin holds a BS/BA in Pre-Med and English from Hillsdale College and is a lecturer for the Rutgers Healthcare MBA program.
Kevin has deep expertise in CV, Oncology, GI, Pulmonology, Rare Diseases, Vaccines, Launch, Commercialization, Patient Access, Patient Advocacy, Payer Strategy & Engagement, Health Policy, HEOR, Pricing & Reimbursement, Specialty Distribution and Retail Channel Management.
Kevin has consistently demonstrated the ability to integrate multiple partners into a launch excellence team who focus on the mission, not their individual functions/business units (both domestically and globally).
At EVERSANA, Kevin helps our EVERSANA® COMPLETE Commercialization partners successfully launch their brand and achieve their commercialization goals.
Articles by Kevin McDermott
Understanding the Inflation Reduction Act: Inflation Rebates
Prescription drug manufacturers routinely implement price increases for a variety of reasons that support their business. With the passage of the Inflation Reduction Act late in 2022, Congress added a twist to these price increases. One provision of the Act, also known as the IRA, implements rebates from pharmaceutical companies to Medicare for price increases that outpace inflation. The Centers for Medicare and Medicaid Services (CMS), the federal agency that oversees Medicare, recently issued guidance for manufacturers to operationalize the statute. Common Elements The IRA mandates that pharmaceutical manufacturers that sell their products prescribed to Medicare Part B and Part D beneficiaries will be subject to these inflation rebates. For […]